$VERU
VERU INC. Stock $veru

$veru Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000086389419000010 Filed on August 08, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2018 Q3
Revenue	$8.730M	$9.727M	$5.200M
YoY Change	67.88%	76.8%	40.92%
Cost Of Revenue	$2.900M	$3.156M	$2.010M
YoY Change	44.28%	30.0%	5.79%
Gross Profit	$5.830M	$6.571M	$3.190M
YoY Change	82.76%	113.75%	78.21%
Gross Profit Margin	66.78%	67.56%	61.35%
Selling, General & Admin	$3.610M	$3.547M	$3.940M
YoY Change	-8.38%	-11.86%	82.41%
% of Gross Profit	61.92%	53.98%	123.51%
Research & Development	$3.610M	$4.866M	$3.030M
YoY Change	19.14%	28.48%	106.12%
% of Gross Profit	61.92%	74.05%	94.98%
Depreciation & Amortization	$110.0K	$130.0K	$120.0K
YoY Change	-8.33%	18.18%	20.0%
% of Gross Profit	1.89%	1.98%	3.76%
Operating Expenses	$7.290M	$8.413M	$6.970M
YoY Change	4.59%	4.66%	92.01%
Operating Profit	-$1.460M	-$1.842M	-$3.780M
YoY Change	-61.38%	-62.9%	105.43%
Interest Expense	-$2.020M	$1.091M	$60.00K
YoY Change	-3466.67%	-20.93%	-300.0%
% of Operating Profit
Other Income/Expense, Net	$20.00K	-$932.5K	$0.00
YoY Change		-47.0%	-100.0%
Pretax Income	-$3.480M	-$2.775M	-$3.710M
YoY Change	-6.2%	-58.74%	32.03%
Income Tax	-$420.0K	-$458.00	$4.210M
% Of Pretax Income
Net Earnings	-$3.060M	-$2.774M	-$7.920M
YoY Change	-61.36%	-65.02%	195.52%
Net Earnings / Revenue	-35.05%	-28.52%	-152.31%
Basic Earnings Per Share
Diluted Earnings Per Share	-$47.03K	-$44.02K	-$143.6K
COMMON SHARES
Basic Shares Outstanding	65.04M	62.79M
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2019 Q2	2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.300M	$8.000M	$3.800M
YoY Change	65.79%	42.86%	15.15%
Cash & Equivalents	$6.295M	$8.039M	$3.760M
Short-Term Investments
Other Short-Term Assets	$1.800M	$1.200M	$1.100M
YoY Change	63.64%	20.0%	57.14%
Inventory	$3.647M	$3.131M	$2.302M
Prepaid Expenses
Receivables	$5.021M	$4.767M	$3.973M
Other Receivables	-$100.0K	$0.00	$0.00
Total Short-Term Assets	$16.81M	$17.14M	$11.18M
YoY Change	50.3%	32.89%	8.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$351.9K	$314.7K	$404.6K
YoY Change	-13.02%	-37.06%	-27.18%
Goodwill	$6.879M	$6.879M	$6.879M
YoY Change	0.0%		0.0%
Intangibles	$20.17M	$20.25M	$20.48M
YoY Change	-1.51%		-1.33%
Long-Term Investments
YoY Change
Other Assets	$988.9K	$684.1K	$965.2K
YoY Change	2.46%	-94.61%	417.7%
Total Long-Term Assets	$36.82M	$36.70M	$37.27M
YoY Change	-1.2%	-9.61%	-17.25%
TOTAL ASSETS
Total Short-Term Assets	$16.81M	$17.14M	$11.18M
Total Long-Term Assets	$36.82M	$36.70M	$37.27M
Total Assets	$53.63M	$53.84M	$48.45M
YoY Change	10.68%	0.64%	-12.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.125M	$3.135M	$3.226M
YoY Change	-3.14%	-10.43%	20.12%
Accrued Expenses	$5.500M	$3.900M	$3.400M
YoY Change	61.76%	85.71%	88.89%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.400M	$4.700M	$6.700M
YoY Change	-19.4%	-26.56%
Total Short-Term Liabilities	$14.02M	$11.66M	$13.55M
YoY Change	3.45%	-8.16%	146.97%
LONG-TERM LIABILITIES
Long-Term Debt	$6.700M	$6.300M	$1.754M
YoY Change	282.03%	31.25%
Other Long-Term Liabilities	$247.2K	$30.00K	$30.00K
YoY Change	723.85%	-70.0%	-97.86%
Total Long-Term Liabilities	$247.2K	$30.00K	$1.784M
YoY Change	-86.14%	-99.39%	27.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.02M	$11.66M	$13.55M
Total Long-Term Liabilities	$247.2K	$30.00K	$1.784M
Total Liabilities	$21.30M	$19.10M	$18.97M
YoY Change	12.25%	8.55%	175.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$70.22M	-$67.16M	-$58.20M
YoY Change	20.65%		69.87%
Common Stock	$672.2K	$670.0K	$574.7K
YoY Change	16.97%		3.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$7.807M	$7.807M	$7.807M
YoY Change	0.0%		0.0%
Treasury Stock Shares	$2.184M	$2.184M	$2.184M
Shareholders Equity	$32.33M	$34.74M	$29.48M
YoY Change
Total Liabilities & Shareholders Equity	$53.63M	$53.84M	$48.45M
YoY Change	10.68%	0.64%	-12.44%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2018 Q3
OPERATING ACTIVITIES
Net Income	-$3.060M	-$2.774M	-$7.920M
YoY Change	-61.36%	-65.02%	195.52%
Depreciation, Depletion And Amortization	$110.0K	$130.0K	$120.0K
YoY Change	-8.33%	18.18%	20.0%
Cash From Operating Activities	-$960.0K	-$530.0K	-$2.820M
YoY Change	-65.96%	-88.35%	-594.74%
INVESTING ACTIVITIES
Capital Expenditures	-$40.00K	-$70.00K	$0.00
YoY Change		40.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$40.00K	-$70.00K	$0.00
YoY Change		40.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-750.0K	2.740M	1.000M
YoY Change	-175.0%	128.33%
NET CHANGE
Cash From Operating Activities	-960.0K	-530.0K	-2.820M
Cash From Investing Activities	-40.00K	-70.00K	0.000
Cash From Financing Activities	-750.0K	2.740M	1.000M
Net Change In Cash	-1.750M	2.140M	-1.820M
YoY Change	-3.85%	-162.94%	-403.33%
FREE CASH FLOW
Cash From Operating Activities	-$960.0K	-$530.0K	-$2.820M
Capital Expenditures	-$40.00K	-$70.00K	$0.00
Free Cash Flow	-$920.0K	-$460.0K	-$2.820M
YoY Change	-67.38%	-89.78%	-586.21%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000863894
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	65038247
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	VERU INC.
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Trading Symbol TradingSymbol	veru
CY2018Q3	us-gaap	Accounts Receivable Gross AccountsReceivableGross	4046733
CY2018Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	3972632
CY2019Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	4766962
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3972632
	us-gaap	Accretion Expense AccretionExpense	122136
CY2018Q2	us-gaap	Accretion Expense AccretionExpense	94858
	us-gaap	Accretion Expense AccretionExpense	363520
CY2019Q2	us-gaap	Accretion Expense AccretionExpense	147223
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4766962
CY2019Q2	us-gaap	Assets Current AssetsCurrent	17142801
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3901418
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3226036
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3134795
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3508556
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1079276
CY2019Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	4838665
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-581519
CY2019Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	109612826
CY2019Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-581519
CY2018Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	95496506
CY2019Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	77000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1381672
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	468207
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	459974
CY2019Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q3	us-gaap	Assets Assets	48452639
CY2019Q2	us-gaap	Assets Assets	53840765
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5266570
CY2018Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	7699000
CY2019Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	7678587
CY2019Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	8527304
CY2019Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2579909
CY2018Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	17586
CY2018Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	622442
CY2018Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	20656420
CY2018Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	13025342
CY2019Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	10626155
CY2018Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	1700
CY2018Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	22902
CY2018Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7631078
CY2018Q3	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	94321
CY2018Q3	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	6843
CY2018Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5326342
CY2019Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	22943868
CY2019Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	12945157
CY2019Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	17586
CY2019Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	843466
CY2019Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	1700
CY2019Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	52257
CY2019Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9998711
CY2019Q2	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	80405
CY2019Q2	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	7318
CY2019Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	106000
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	670025
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	574687
CY2018Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	2195865
CY2018Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	6973047
CY2017Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
	us-gaap	Net Income Loss NetIncomeLoss	-16018878
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	56656
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	101981
CY2019Q2	us-gaap	Goodwill Goodwill	6878932
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	77000000
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	154000000
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57468660
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3277602
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5577440
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3759509
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8039116
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2299838
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4279607
CY2017Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	38103
CY2018Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	36161
CY2018Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	36201
CY2019Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	33143
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	35772
CY2018Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	30202
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	76479
CY2019Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	21909
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1572809
CY2018Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1255062
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3187972
CY2019Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	922144
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	206447
CY2018Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	69000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	231926
CY2018Q3	us-gaap	Assets Current AssetsCurrent	11182516
	us-gaap	Basis Of Accounting BasisOfAccounting	<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;">Note 1 – Basis of Presentation</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">The accompanying unaudited interim condensed consolidated financial statements for Veru Inc. (“we,” “our,” “us,” “Veru” or the “Company”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting of interim financial information. Pursuant to these rules and regulations, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted, although the Company believes that the disclosures made are adequate to make the information not misleading. Accordingly, these statements do not include all the disclosures normally required by U.S. GAAP for annual financial statements and should be read in conjunction with Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in this report and the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended </font><font style="display: inline;">September 30, 2018</font><font style="display: inline;">. The accompanying condensed consolidated balance sheet as of </font><font style="display: inline;">September 30, 2018</font><font style="display: inline;"> has been derived from our audited financial statements. The unaudited condensed consolidated statements of operations for the three and nine months ended June 30, 2019 and cash flows for the </font><font style="display: inline;">nine months ended June 30, 2019</font><font style="display: inline;"> are not necessarily indicative of the results to be expected for any future period or for the fiscal year ending </font><font style="display: inline;">September 30, 201</font><font style="display: inline;">9</font><font style="display: inline;">.  </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">The preparation of our unaudited interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements contain all adjustments (consisting of only normally recurring adjustments) necessary to present fairly the financial position and results of operations as of the dates and for the periods presented.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Principles of consolidation and nature of operations</font><font style="display: inline;">: Veru Inc. is </font><font style="display: inline;color:#000000;">referred to in these notes collectively with its subsidiaries as “we,” “our,” “us,” “Veru” or the “Company.” </font><font style="display: inline;">The consolidated financial statements include the accounts of Veru and its wholly owned subsidiaries, Aspen Park Pharmaceuticals, Inc. (“APP”) and The Female Health Company Limited, and The Female Health Company Limited’s wholly owned subsidiary, The Female Health Company (UK) plc (The Female Health Company Limited and The Female Health Company (UK) plc, collectively, the “U.K. subsidiary”), and The Female Health Company (UK) plc’s wholly owned subsidiary, The Female Health Company (M) SDN.BHD (the “Malaysia subsidiary”). All significant intercompany transactions and accounts have been eliminated in consolidation. Prior to the completion of the October 31, 2016 acquisition (the “APP Acquisition”) of APP through the merger of a wholly owned subsidiary of the Company into APP, the Company had been a single product company engaged in marketing, manufacturing and distributing a consumer healthcare product, the FC2 </font><font style="display: inline;">Female Condom/FC2 Internal Condom® (“FC2”)</font><font style="display: inline;">.  The completion of the APP Acquisition transitioned the Company into a biopharmaceutical company </font><font style="display: inline;">focused on oncology and urology</font><font style="display: inline;"> with multiple drug products under clinical development.  Most of the Company’s net revenues during the three and nine months ended June 30, 2019 and 2018 were derived from sales of FC2.  </font> </p> <p style="margin:0pt;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Reclassifications</font><font style="display: inline;">:  </font><font style="display: inline;">Certain prior period amounts in the accompanying unaudited interim condensed consolidated financial statements have been reclassified to conform with the current period presentation. </font><font style="display: inline;">These reclassifications had no effect on </font><font style="display: inline;color:#000000;">the results of operations or financial position for any period presented.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;text-decoration:underline;">Cash concentration</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">: The Company’s cash is maintained primarily in three financial institutions, located in Chicago, Illinois; London, England and Kuala Lumpur, Malaysia.</font> </p> <p style="margin:0pt;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Restricted cash</font><font style="display: inline;">: Restricted cash relates to security provided to one of the Company’s U.K. banks for performance bonds issued in favor of customers. The Company has a facility of </font><font style="display: inline;">$250,000</font><font style="display: inline;"> for such performance bonds.  Such security has been extended infrequently and only on occasions where it has been a contract term expressly stipulated as an absolute requirement by the customer or its provider of funds. The expiration of the bond is defined by the completion of the event such as, but not limited to, a period of time after the product has been distributed or expiration of the product shelf life. The Company had </font><font style="display: inline;">no</font><font style="display: inline;"> restricted cash at June 30, 2019. Restricted cash was  </font><font style="display: inline;">$135,000</font><font style="display: inline;"> at September 30, 2018 and is included in cash on the accompanying unaudited condensed consolidated balance sheets. </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Patents and trademarks</font><font style="display: inline;">: The costs for patents and trademarks are expensed when incurred.  </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Deferred financing costs</font><font style="display: inline;">:</font><font style="display: inline;font-weight:bold;font-style:italic;"> </font><font style="display: inline;">Costs incurred in connection with the </font><font style="display: inline;">common stock purchase agreement discussed in Note 9 </font><font style="display: inline;">have been included in other assets on the accompanying unaudited condensed consolidated balance sheets at June 30, 2019 and September 30, 2018. When shares of the Company’s common stock are sold under the common stock purchase agreement, a pro-rata portion of the deferred costs is recorded to additional paid-in-capital. </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">As discussed in Note 9, in connection with the </font><font style="display: inline;">common stock offering that closed on October 1, 2018, we incurred c</font><font style="display: inline;">osts </font><font style="display: inline;">of approximately </font><font style="display: inline;">$190,000</font><font style="display: inline;"> through September 30, 2018. This amount was included in </font><font style="display: inline;">other assets on the accompanying unaudited condensed consolidated balance sheet at September 30, 2018. These costs were charged to additional paid-in capital in the nine months ended June 30, 2019 after the common stock offering was closed.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">Costs incurred in connection with the </font><font style="display: inline;">issuance of debt discussed in Note 8 are presented as a reduction of the debt on the accompanying unaudited condensed consolidated balance sheets at June 30, 2019 and September 30, 2018. These issuance costs are being amortized using the effective interest method over the expected repayment period of the debt, which is currently estimated to occur in the fourth quarter of fiscal 2021. The amortization is included in interest expense on the accompanying unaudited condensed consolidated statements of operations.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Fair value measurements</font><font style="display: inline;">: Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820 –</font><font style="display: inline;font-style:italic;"> Fair Value Measurements and Disclosures,</font><font style="display: inline;"> defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC Topic 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to us as of the reporting dates. Accordingly, the estimates presented in the accompanying unaudited condensed consolidated financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments. See Note 3 </font><font style="display: inline;">for a discussion of fair value measurements</font><font style="display: inline;">.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;">The carrying amounts reported in the accompanying unaudited condensed consolidated balance sheets for cash, accounts receivable, accounts payable and other accrued liabilities approximate their fair value based on the short-term nature of these instruments. The carrying value of long-term debt, taking into consideration debt discounts and related derivative instruments, is estimated to approximate fair value.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Derivative instruments</font><font style="display: inline;">: The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. The Company reviews the terms of debt instruments it enters into to determine whether there are embedded derivative instruments, which are required to be bifurcated and accounted for separately as derivative financial instruments. Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and are recognized at fair value with changes in fair value recognized as either a gain or loss in earnings. Liabilities incurred in connection with an embedded derivative are discussed in Note 8.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Revenue recognition</font><font style="display: inline;">: Revenue is recognized when control of the promised goods is transferred to the customer in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those products. See Note 4 for further discussion on revenue.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Research and development costs</font><font style="display: inline;">: Research and development costs are expensed as they are incurred and include salaries and benefits, clinical trial costs and contract services. Nonrefundable advance payments made for goods or services to be used in research and development activities are deferred and capitalized until the goods have been delivered or the related services have been performed. If the goods are no longer expected to be delivered or the services are no longer expected to be performed, the Company would be required to expense the related capitalized advance payments. The Company did not have any capitalized nonrefundable advance payments as of June 30, 2019 and September 30, 2018.</font> </p> <p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">The Company records estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical studies and clinical trials and contract manufacturing activities. These costs are a significant component of the Company’s research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. However, the status and timing of actual services performed, number of patients enrolled and the rate of patient enrollments may vary from the Company’s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company’s accruals could materially affect the Company’s results of operations. </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Share-based compensation</font><font style="display: inline;">: The Company recognizes share-based compensation expense in connection with its share-based awards, based on the estimated fair value of the awards on the date of grant, on a straight-line basis over the vesting period. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, including estimates of the expected life of the share-based award, stock price volatility and risk-free interest rates.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;"></font> </p> <p style="margin:0pt;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;text-decoration:underline;">Advertising</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">: The Company's policy is to expense advertising costs as incurred. Advertising costs were immaterial to the Company’s results of operations for the three and nine months ended June 30, 2019 and 2018.</font> </p> <p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;"> </font> </p> <p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;text-decoration:underline;">Income taxes</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">: The Company files separate income tax returns for its foreign subsidiaries. FASB ASC Topic 740 requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are also provided for carryforwards for income tax purposes. In addition, the amount of any future tax benefits is reduced by a valuation allowance to the extent such benefits are not expected to be realized.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"> </font> </p> <p style="margin:0pt;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;text-decoration:underline;">Foreign currency translation and operations</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">: Effective October 1, 2009, the Company determined that there were significant changes in facts and circumstances, triggering an evaluation of its subsidiaries’ functional currency. The evaluation indicated that the U.S. dollar is the currency with the most significant influence upon the subsidiaries. Because all of the U.K. subsidiary's future sales and cash flows would be denominated in U.S. dollars following the October 2009 cessation of production of the Company’s first-generation product, FC1, the U.K. subsidiary adopted the U.S. dollar as its functional currency effective October 1, 2009. As the Malaysia subsidiary is a direct and integral component of the U.K. parent’s operations, it, too, adopted the U.S. dollar as its functional currency as of October 1, 2009. The consistent use of the U.S. dollar as the functional currency across the Company reduces its foreign currency risk and stabilizes its operating results. The cumulative foreign currency translation loss included in accumulated other comprehensive loss was </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$0.6</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> million as of June 30, 2019 and September 30, 2018. Assets located outside of the U.S. totaled approximately </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$6.1</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> million and </font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">$5.2</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;"> million at June 30, 2019 and September 30, 2018, respectively.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">    </font> </p> <p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;text-decoration:underline;">Other comprehensive loss</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">: Accounting principles generally require that recognized revenue, expenses, gains and losses be included in net loss. Although certain changes in assets and liabilities, such as foreign currency translation adjustments, are reported as a separate component of the equity section of the accompanying unaudited condensed consolidated balance sheets, these items, along with net loss, are components of other comprehensive loss.</font> </p> <p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;"></font> </p> <p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;">The U.S. parent company and its U.K. subsidiary routinely purchase inventory produced by its Malaysia subsidiary for sale to their respective customers. These intercompany trade accounts are eliminated in consolidation. The Company’s policy and intent is to settle the intercompany trade account on a current basis.  Since the U.K. and Malaysia subsidiaries adopted the U.S. dollar as their functional currencies effective October 1, 2009, no foreign currency gains or losses from intercompany trade are recognized.  For the three and nine months ended June 30, 2019 and 2018, comprehensive loss is equivalent to the reported net loss.</font><font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"> </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Recently Issued Accounting Pronouncements</font><font style="display: inline;">:  </font><font style="display: inline;color:#000000;">In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014</font><font style="display: inline;color:#000000;">‑09, </font><font style="display: inline;font-style:italic;color:#000000;">Revenue from Contracts with Customers (Topic 606)</font><font style="display: inline;color:#000000;">. This new accounting guidance on revenue recognition provides for a single five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. The new guidance also requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. The Company adopted the new guidance on October 1, 2018 using the modified retrospective method and elected to apply the guidance only to contracts that were not completed as of the date of adoption. The adoption of this guidance did not have a material effect on our consolidated financial statements and related disclosures. See Note 4 for disclosures relating to the Company's revenue recognition.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">In February 2016, the FASB issued ASU 2016</font><font style="display: inline;">‑02, </font><font style="display: inline;font-style:italic;">Leases (Topic 842)</font><font style="display: inline;">,  </font><font style="display: inline;color:#000000;">which requires that lessees recognize a right-of-use asset and a lease liability for all leases with lease terms greater than twelve months in the balance sheet. ASU 2016-02 distinguishes leases as either a finance lease or an operating lease, which affects how the leases are measured and presented in the statement of operations and statement of cash flows, and requires disclosure of</font><font style="display: inline;"> key information about leasing arrangements.  ASU 2016</font><font style="display: inline;">‑02 </font><font style="display: inline;color:#000000;">is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required upon adoption.</font><font style="display: inline;"> Early adoption is permitted. I</font><font style="display: inline;color:#000000;">n July 2018, the FASB issued ASU No. 2018</font><font style="display: inline;color:#000000;">‑10, </font><font style="display: inline;font-style:italic;color:#000000;">Codification Improvements to Topic 842, Leases</font><font style="display: inline;color:#000000;"> to clarify the implementation guidance and ASU No. 2018</font><font style="display: inline;color:#000000;">‑11, </font><font style="display: inline;font-style:italic;color:#000000;">Leases (Topic 842) Targeted Improvements</font><font style="display: inline;color:#000000;">. This updated guidance provides an optional transition method, which allows for the initial application of the new accounting standard at the adoption date and the recognition of a cumulative-effect adjustment to the opening balance of retained earnings as of the beginning of the period of adoption. </font><font style="display: inline;">I</font><font style="display: inline;color:#000000;">n December 2018, the FASB issued ASU 2018-20, </font><font style="display: inline;font-style:italic;color:#000000;">Leases (Topic 842): Narrow-Scope Improvements for Lessors</font><font style="display: inline;color:#000000;"> to address certain implementation issues facing lessors when adopting ASU 2016</font><font style="display: inline;color:#000000;">‑02. </font><font style="display: inline;">I</font><font style="display: inline;color:#000000;">n March 2019, the FASB issued ASU 2019</font><font style="display: inline;color:#000000;">‑01, </font><font style="display: inline;font-style:italic;color:#000000;">Leases (Topic 842): Codification Improvements</font><font style="display: inline;color:#000000;"> to address, among other things, certain transition disclosure requirements subsequent to the adoption of ASU 2016</font><font style="display: inline;color:#000000;">‑02. The Company will adopt the new accounting standard </font><font style="display: inline;">on October 1, 2019 and intends to elect certain </font><font style="display: inline;color:#000000;">practical expedients, including the optional transition method that allows for the application of the new standard at its adoption date with no restatement of prior period amounts</font><font style="display: inline;">.  </font><font style="display: inline;color:#000000;">We are </font><font style="display: inline;">evaluating the effect of the new guidance on our consolidated financial statements and related disclosures. The primary effect of adoption will be recording right-of-use assets and corresponding lease obligations for current operating leases. The adoption is expected to have a material impact on the Company’s consolidated balance sheets, but not on the consolidated statements of operations or cash flows. The Company is reviewing current accounting policies and related disclosures, and evaluating changes to business processes and controls to support adoption of the new standard.</font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">In November 2016, the FASB issued ASU 2016-18, </font><font style="display: inline;font-style:italic;">Statement of Cash Flows</font><font style="display: inline;"> </font><font style="display: inline;font-style:italic;">(Topic 230):</font><font style="display: inline;"> </font><font style="display: inline;font-style:italic;">Restricted Cash</font><font style="display: inline;">. The purpose of ASU 2016</font><font style="display: inline;">‑18 is to clarify guidance and presentation related to restricted cash in the statements of cash flows as well as increased disclosure requirements. It requires beginning-of-period and end-of-period total amounts shown on the statements of cash flows to include cash and cash equivalents as well as restricted cash and restricted cash equivalents. We adopted ASU 2016</font><font style="display: inline;">‑18 effective October 1, 2018. The adoption of ASU 2016</font><font style="display: inline;">‑18 did not have a material effect on the presentation of our consolidated statements of cash flows or related disclosures.  </font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"></font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;">In January 2017, the FASB issued ASU 2017</font><font style="display: inline;color:#000000;">‑04, </font><font style="display: inline;font-style:italic;color:#000000;">Intangibles - Goodwill and Other Topics </font><font style="display: inline;font-style:italic;color:#000000;">(Topic 350)</font><font style="display: inline;font-style:italic;color:#000000;">: Simplifying the Test for Goodwill Impairment</font><font style="display: inline;color:#000000;">. The purpose of ASU 2017</font><font style="display: inline;color:#000000;">‑04 is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the impaired fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this amendment, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit's fair value. ASU 2017</font><font style="display: inline;color:#000000;">‑04 is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. We do not expect the adoption of ASU 2017</font><font style="display: inline;color:#000000;">‑04 to have a material effect on our financial position or results of operations.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;"></font> </p> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;">In May 2017, the FASB issued ASU 2017</font><font style="display: inline;color:#000000;">‑09, </font><font style="display: inline;font-style:italic;color:#000000;">Compensation - Stock Compensation </font><font style="display: inline;font-style:italic;color:#000000;">(Topic 718)</font><font style="display: inline;font-style:italic;color:#000000;">: Scope of Modification Accounting</font><font style="display: inline;color:#000000;">. The purpose of ASU 2017</font><font style="display: inline;color:#000000;">‑09 is to provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. </font><font style="display: inline;color:#000000;">The amendments in ASU 2017</font><font style="display: inline;color:#000000;">‑09 should be applied prospectively to an award modified on or after the adoption date. We adopted </font><font style="display: inline;color:#000000;">ASU 2017</font><font style="display: inline;color:#000000;">‑09 effective October 1, 2018. The adoption of ASU 2017</font><font style="display: inline;color:#000000;">‑09 did not have a material effect on our financial position or results of operations.  </font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;"></font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;">In June 2018, the FASB issued ASU 2018</font><font style="display: inline;color:#000000;">‑07, </font><font style="display: inline;font-style:italic;color:#000000;">Compensation - Stock Compensation </font><font style="display: inline;font-style:italic;color:#000000;">(Topic 718)</font><font style="display: inline;font-style:italic;color:#000000;">: Improvements to Nonemployee Share-Based Payment Accounting</font><font style="display: inline;color:#000000;">. The purpose of ASU 2018-07 is to expand the scope of </font><font style="display: inline;font-style:italic;color:#000000;">Topic 718, Compensation—Stock Compensation</font><font style="display: inline;color:#000000;"> (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. ASU 2018-07 will be effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than the Company’s adoption date of </font><font style="display: inline;font-style:italic;color:#000000;">Topic 606, Revenue from Contracts with Customers</font><font style="display: inline;color:#000000;">. The Company has issued share-based payments to nonemployees in the past but is not able to predict the amount of future share-based payments to nonemployees, if any. The adoption of ASU 2018</font><font style="display: inline;color:#000000;">‑07 is not expected to have a material effect on our financial position or results of operations but should simplify the process by which the Company measures compensation expense for share-based payments to nonemployees.</font><font style="display: inline;font-weight:bold;"> </font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"> </font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;color:#000000;">In August 2018, the FASB issued ASU 2018</font><font style="display: inline;color:#000000;">‑13, </font><font style="display: inline;font-style:italic;color:#000000;">Fair Value Measurement (Topic 820): Disclosure Framework – Change to the Disclosure Requirements for Fair Value Measurement</font><font style="display: inline;color:#000000;">. ASU 2018</font><font style="display: inline;color:#000000;">‑13 </font><font style="display: inline;color:#000000;">modifies the disclosure requirements by adding, removing, and modifying certain required disclosures for fair value measurements for assets and liabilities disclosed within the fair value hierarchy. ASU 2018</font><font style="display: inline;color:#000000;">‑13 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 and early adoption is permitted</font><font style="display: inline;color:#000000;">. The adoption of ASU 2018</font><font style="display: inline;color:#000000;">‑13 is not expected to have a material effect on our financial position or results of operations </font><font style="display: inline;color:#000000;">as it modifies disclosure requirements only.</font> </p> <p style="margin:0pt;line-height:normal;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;"> </font> </p> <p><font size="1"> </font></p> </div> </div>
CY2018Q3	us-gaap	Cash Cash	3759509
CY2019Q2	us-gaap	Cash Cash	8039116
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	933000
	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2367633
CY2019Q2	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	716442
	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	388191
CY2018Q2	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	265618
	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-23887
CY2019Q2	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-1025
CY2019Q2	us-gaap	Inventory Net InventoryNet	3130720
CY2018Q3	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	2701570
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53840765
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	13552927
CY2019Q2	us-gaap	Liabilities Liabilities	19104598
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67002483
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55284956
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	64818779
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Arial Narrow;font-size: 10pt"> <font style="display: inline;font-family:Times New Roman;font-size:10pt;text-decoration:underline;">Cash concentration</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">: The Company’s cash is maintained primarily in three financial institutions, located in Chicago, Illinois; London, England and Kuala Lumpur, Malaysia.</font> </p> <p><font size="1"> </font></p> </div> </div>
CY2018Q3	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	4000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5075470
CY2018Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2427542
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7250895
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3155902
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3367000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	20413
CY2018Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	88161
CY2019Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	201167
CY2018Q3	us-gaap	Deferred Revenue DeferredRevenue	187000
CY2019Q2	us-gaap	Deferred Revenue DeferredRevenue	0
CY2018Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	187159
CY2018Q3	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	8543758
CY2019Q2	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	8574448
CY2018Q3	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	8543758
CY2019Q2	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	8574448
CY2018Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	10595518
CY2018Q3	us-gaap	Deferred Tax Liabilities Gross Noncurrent DeferredTaxLiabilitiesGrossNoncurrent	844758
CY2019Q2	us-gaap	Deferred Tax Liabilities Gross Noncurrent DeferredTaxLiabilitiesGrossNoncurrent	895861
CY2018Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	844758
CY2019Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	895861
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2018Q3	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	6692718
CY2019Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2019Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	30000
CY2018Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2465657
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1206003
CY2018Q3	veru	Deferred Tax Liabilities In Process R And D DeferredTaxLiabilitiesInProcessRAndD	4675860
CY2018Q3	veru	Deferred Tax Liabilities Developed Technology DeferredTaxLiabilitiesDevelopedTechnology	549318
CY2019Q2	veru	Deferred Tax Assets Foreign Capital Allowance DeferredTaxAssetsForeignCapitalAllowance	102098
CY2019Q2	veru	Deferred Tax Liabilities Developed Technology DeferredTaxLiabilitiesDevelopedTechnology	502987
CY2019Q2	veru	Deferred Tax Liabilities In Process R And D DeferredTaxLiabilitiesInProcessRAndD	4675860
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	30000
CY2019Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2900000
CY2018Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2477729
CY2019Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2245803
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2018Q2	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2019Q2	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2018Q2	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2019Q2	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	3319000
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	399000
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	246000
CY2018Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	3718000
CY2018Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2426000
CY2019Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2672000
CY2018Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	422271
CY2019Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	654197
CY2018Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2900000
CY2019Q2	us-gaap	Treasury Stock Value TreasuryStockValue	7806605
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4305970
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-118124
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	965152
CY2019Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	684091
CY2019Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3823246
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	404552
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	314690
CY2019Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-16601
CY2018Q3	veru	Residual Royalty Agreement Noncurrent ResidualRoyaltyAgreementNoncurrent	1753805
CY2018Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1591
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-57788
	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet	-399000
CY2018Q2	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet	-378000
	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet	-246000
CY2019Q2	us-gaap	Gain Loss On Derivative Instruments Held For Trading Purposes Net GainLossOnDerivativeInstrumentsHeldForTradingPurposesNet	157000
CY2018Q3	us-gaap	Goodwill Goodwill	6878932
	us-gaap	Gross Profit GrossProfit	5585745
CY2018Q2	us-gaap	Gross Profit GrossProfit	3074188
	us-gaap	Gross Profit GrossProfit	15824089
CY2019Q2	us-gaap	Gross Profit GrossProfit	6571158
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19361217
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6724377
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8839702
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2774534
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3342339
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1206131
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	117207
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-458
CY2018Q2	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	933000
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5040855
CY2018Q2	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1412119
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1856337
CY2019Q2	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-582652
	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	13564
CY2018Q2	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	862
	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	7052
CY2019Q2	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	2269
	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-963608
CY2018Q2	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-15213
	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-439952
CY2019Q2	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-138089
	us-gaap	Income Tax Reconciliation Tax Credits Foreign IncomeTaxReconciliationTaxCreditsForeign	-1311429
CY2018Q2	us-gaap	Income Tax Reconciliation Tax Credits Foreign IncomeTaxReconciliationTaxCreditsForeign	-1311429
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	775923
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2339947
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	791272
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-46894
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	454324
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	566557
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-253536
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-187159
	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	-399000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1922160
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-67158560
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58201651
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4978319
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-932532
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
	us-gaap	Operating Expenses OperatingExpenses	22683605
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	8038916
	us-gaap	Operating Expenses OperatingExpenses	20802408
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	8413160
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17097860
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4964728
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1842002
	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	-246000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-114037
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	941188
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	275586
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	68578
CY2018Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	20900000
CY2019Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	20900000
CY2018Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20477729
CY2019Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	20245803
	us-gaap	Interest Expense InterestExpense	1730717
CY2018Q2	us-gaap	Interest Expense InterestExpense	1380122
	us-gaap	Interest Expense InterestExpense	3627971
CY2019Q2	us-gaap	Interest Expense InterestExpense	1091276
CY2018Q3	us-gaap	Inventory Net InventoryNet	2302030
CY2018Q3	us-gaap	Liabilities Liabilities	18971221
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48452639
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11663285
CY2019Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	4660572
CY2019Q2	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	4489540
	us-gaap	Loss Contingency Accrual Carrying Value Period Increase Decrease LossContingencyAccrualCarryingValuePeriodIncreaseDecrease	0
CY2019Q2	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	10000000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11078752
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8884760
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-47696
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-74948
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8731218
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4530205
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-4257152
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-3831218
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-7930508
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-2148798
	us-gaap	Net Income Loss NetIncomeLoss	-8956909
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-4034035
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-2774076
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2263357
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1759649
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3861383
CY2019Q2	veru	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	1464298
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3991346
CY2018Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	227208
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	642485
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	4047207
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7822724
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3787562
CY2018Q3	veru	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	981357
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-600000
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-600000
CY2019Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2403620
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1730717
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-3627971
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-15516
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	64
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	70376
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	18345
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-39155
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	261172
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	266923
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	47696
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	74948
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	77000000
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	154000000
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1148345
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;text-decoration:underline;">Reclassifications</font><font style="display: inline;">:  </font><font style="display: inline;">Certain prior period amounts in the accompanying unaudited interim condensed consolidated financial statements have been reclassified to conform with the current period presentation. </font><font style="display: inline;">These reclassifications had no effect on </font><font style="display: inline;color:#000000;">the results of operations or financial position for any period presented.</font> </p> <p><font size="1"> </font></p> </div> </div>
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	9131967
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3600000
	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	10000000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	66000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	200000
CY2018Q3	veru	Allowance For Sales And Payment Term Discounts AllowanceForSalesAndPaymentTermDiscounts	37900
CY2019Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	2183704
CY2018Q3	us-gaap	Treasury Stock Value TreasuryStockValue	7806605
CY2019Q2	veru	Allowance For Sales And Payment Term Discounts AllowanceForSalesAndPaymentTermDiscounts	38560
CY2018Q3	veru	Deferred Tax Assets Foreign Capital Allowance DeferredTaxAssetsForeignCapitalAllowance	102098
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10138524
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4866114
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	135000
CY2019Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	0
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10661215
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5501730
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23074984
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9727060
	us-gaap	Revenues Revenues	10661215
CY2018Q2	us-gaap	Revenues Revenues	5501730
	us-gaap	Revenues Revenues	23074984
CY2019Q2	us-gaap	Revenues Revenues	9727060
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	33544017
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62917362
	veru	Allowance For Doubtful Accounts Receivable Net Write Offs And Recoveries AllowanceForDoubtfulAccountsReceivableNetWriteOffsAndRecoveries	5000
	veru	Allowance For Doubtful Accounts Receivable Net Write Offs And Recoveries AllowanceForDoubtfulAccountsReceivableNetWriteOffsAndRecoveries	3058
	veru	Amortization Of Deferred Stock Issuance Costs AmortizationOfDeferredStockIssuanceCosts	56656
	veru	Amortization Of Deferred Stock Issuance Costs AmortizationOfDeferredStockIssuanceCosts	101981
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	34736167
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10869535
CY2018Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4024146
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10663884
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3547046
	us-gaap	Share Based Compensation ShareBasedCompensation	1079276
	us-gaap	Share Based Compensation ShareBasedCompensation	1381672
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed	Monte Carlo Simulation
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	48453205
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	44750588
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	41331218
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	35870028
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	29481418
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	36881843
CY2017Q4	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	347081
CY2018Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2000000
CY2019Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	3600000
CY2018Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	9131967
CY2017Q4	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	207454
CY2018Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	411848
CY2018Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	459974
CY2018Q4	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	417256
CY2019Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	496209
CY2019Q2	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	468207
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	66000
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	200000
CY2018Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	2183704
CY2019Q2	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	2400000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53432404
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53789409
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	62745355
	veru	Depreciation And Other Amortization DepreciationAndOtherAmortization	131920
	veru	Depreciation And Other Amortization DepreciationAndOtherAmortization	126084
	veru	Income Tax Reconciliation Effect Of Deemed Dividends IncomeTaxReconciliationEffectOfDeemedDividends	66182
CY2019Q2	veru	Income Tax Reconciliation Effect Of Deemed Dividends IncomeTaxReconciliationEffectOfDeemedDividends	2554
CY2018Q1	veru	Net Proceeds After Fees And Expenses NetProceedsAfterFeesAndExpenses	9900000
	veru	Number Of Class Action Lawsuits Filed NumberOfClassActionLawsuitsFiled	2
	veru	Provision Charges To Expenses ProvisionChargesToExpenses	3058
CY2019Q2	veru	Residual Royalty Agreement Noncurrent ResidualRoyaltyAgreementNoncurrent	1824745
	veru	Shares Issued In Connection With Common Stock Purchase SharesIssuedInConnectionWithCommonStockPurchase	347081
CY2018	veru	Stock Issuance Costs Incurred StockIssuanceCostsIncurred	190000

Files In Submission

Name	View Source	Status
0000863894-19-000010-index-headers.html	Edgar Link	pending
0000863894-19-000010-index.html	Edgar Link	pending
0000863894-19-000010.txt	Edgar Link	pending
0000863894-19-000010-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
veru-20190630.xml	Edgar Link	completed
veru-20190630.xsd	Edgar Link	pending
veru-20190630x10q.htm	Edgar Link	pending
veru-20190630xex31_1.htm	Edgar Link	pending
veru-20190630xex31_2.htm	Edgar Link	pending
veru-20190630xex32_1.htm	Edgar Link	pending
veru-20190630_cal.xml	Edgar Link	unprocessable
veru-20190630_def.xml	Edgar Link	unprocessable
veru-20190630_lab.xml	Edgar Link	unprocessable
veru-20190630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VERU
VERU INC. Stock $veru

2019 Q3 Form 10-Q Financial Statement

#000086389419000010 Filed on August 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VERU VERU INC. Stock $veru

2019 Q3 Form 10-Q Financial Statement

#000086389419000010 Filed on August 08, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VERU
VERU INC. Stock $veru